Clinical trials: Lung Tumors
Non-small-cell Lung Cancer, Carcinoma, Non-Small-Cell Lung
Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer and Discovery of New Biomarkers
Lung cancer patients have a poor prognosis and only around 20 % is alive after 5 years. However, for advanced non-small cell lung cancer immunotherapy has become a cornerstone of treatment.
- Conditions
- Non-small-cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Lung Neoplasm
- Trial name
- LimBio (NCT03658460)
- Testing
- DNA sequencing
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Aalborg University Hospital
Lung Cancer
Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC
Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy and subsequent concomitantly with radiotherapy (RT) in patients with lung cancer (NSCLC) locally advanced unresectable
- Trial name
- NORA (NCT02709720)
- Testing
- Vinorelbine, Cisplatin, Radiotherapy
- Where
- 18 sites in Spain
- Volunteers
- 68 people
- Sponsor
- Spanish Lung Cancer Group
Atrial Fibrillation, COVID-19
Positron Emission Tomography (PET) Imaging of Thrombosis
The purpose of the study is to evaluate a new radiotracer called 64Cu-FBP8 for PET-MR imaging of thrombosis. The tracer has the potential of detecting thrombosis anywhere in the body, for instance in the left atrial appendage of…
- Conditions
- Atrial Fibrillation, COVID-19, Cancer, Thrombosis
- Trial name
- NCT03830320
- Testing
- [64Cu]FBP8, PET/MR, Blood Collection
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Lung Cancer
Hypofractionated Radiotherapy for Lung Cancer
The purpose of this trial is to pilot reducing the duration of radiation treatment for lung cancer patients from 6 to 5 weeks using tomotherapy. Specific patient doses will be based on tumor volume being treated.
- Trial name
- NCT00214123
- Testing
- radiation therapy (radiotherapy)
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- University of Wisconsin, Madison
Non-Small Cell Lung Cancer (NSCLC)
Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab
RATIONALE: Classically the evaluation of response in lung cancer has been based in comparing pre \& post treatment tumour volume by means of studying changes in the diameter of the selected target lesions by RECIST.
- Trial name
- NCT02316327
- Testing
- gemcitabine, cisplatin and bevacizumab
- Where
- Spain
- Volunteers
- 19 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Carcinoma, Non-Small-Cell Lung
Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
There is little information of Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 patients analyzed in the clinical trials.
- Trial name
- NCT00906061
- Testing
- Gemcitabine and Docetaxel
- Where
- 12 sites in Spain
- Volunteers
- 76 people
- Sponsor
- Hospital Arnau de Vilanova
Non-small Cell Lung Cancer
Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer
A phase 2 study to evaluate efficacy of oral seliciclib in treating non-small cell lung cancer (NSCLC).
- Trial name
- NCT00372073
- Testing
- seliciclib
- Where
- 20 sites in United States
- Volunteers
- 187 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Lung Cancer, EGFR Gene Mutation
Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies
In this study, patients who are taking oral tyrosine kinase inhibitor (TKI) therapy for lung cancer will be asked to participate in a remote monitoring system for up to 24 weeks.
- Conditions
- Lung Cancer, EGFR Gene Mutation, EGFR, ALK Gene Mutation
- Trial name
- Lung001 (NCT05370469)
- Testing
- Sensus Smartwatch Application, RX Cap, Fitbit Sense
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Virginia
Myeloma, Long COVID
Understanding Patterns of Fatigue in Health and Disease
Fatigue is a common symptom and can be the most distressing symptom of a range of medical conditions. This Ecological Momentary Assessment study will investigate lived experiences of fatigue in detail in individuals with myeloma…
- Conditions
- Myeloma, Long COVID, Heart Failure
- Trial name
- FATIGUE (NCT05622669)
- Testing
- Observational
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Aberdeen
Solid Tumor, Adult
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
T Cell Receptor-engineered T-cell therapy (TCR T-cell therapy) offers a potentially transformative approach to treating cancer, but is currently limited by the lack of known targets (Maus and June, 2016; Ping et al., 2018).
- Trial name
- NCT05230186
- Testing
- Tumor Biopsy
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- TScan Therapeutics, Inc.
Non-small Cell Lung Cancer
Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer
The purpose of this study is to study the effect of hormone therapies (androgen pathway modification) on the outcomes of patients with lung cancer.
- Trial name
- NCT02055170
- Testing
- finasteride 5mg oral daily
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- CancerCare Manitoba
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
This phase I/II trial studies the best dose and effect of pimasertib in combination with bintrafusp alfa in treating patients with cancer that has spread to the brain (brain metastases).
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Hormone Receptor Positive Breast Adenocarcinoma
- Trial name
- NCT04789668
- Testing
- Bintrafusp Alfa, Pimasertib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
PDL1 Gene Mutation, Non Small Cell Lung Cancer
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
This is a Phase 0/1, First-in-Human (FIH), study to evaluate safety, tolerability of 177Lu-RAD204 in participants with selected solid tumors, and to determine the MTD and/or recommended dose for future exploration.
- Conditions
- PDL1 Gene Mutation, Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), TNBC, Triple Negative Breast Cancer
- Trial name
- NCT06305962
- Testing
- 177Lu-RAD204
- Where
- 6 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Radiopharm Theranostics, Ltd
NSCLC
A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation
The primary objective of this study is to evaluate the safety and tolerability of TY-9591, with dose-escalation stage and dose-expansion stage.
- Trial name
- NCT04204473
- Testing
- TY-9591(10mg,40mg) qd. po
- Where
- China
- Volunteers
- 105 people
- Sponsor
- TYK Medicines, Inc
Lung Cancer
The INSPIRE-Lung Study
LungTalk and leveraging Facebook-targeted Advertisement (FBTA) addresses the call to develop and test multi-level, cancer communication interventions using innovative methods and designs.
- Trial name
- NCT05824273
- Testing
- LungTalk, Non-tailored intervention - Standard of practice
- Where
- United States
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- Hackensack Meridian Health
Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Emulation of the KEYNOTE-042 (NCT02220894) Trial Using Specialty Oncology Electronic Health Records Databases
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Trial name
- NCT07485179
- Testing
- Initiation of pembrolizumab, Initiation of chemotherapy
- Where
- United States
- Volunteers
- 770 people
- Sponsor
- Brigham and Women's Hospital
Non Small Cell Lung Cancer
Changes in Circulating Tumor-Specific DNA in Patients With Non-Metastatic Non-Small Cell Lung Cancer
The purpose of this research study is to evaluate a blood test to measure circulating tumor DNA (ctDNA). It is hypothesized that ctDNA may identify patients who can be considered for additional therapy.
- Trial name
- NCT03746262
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
Oncology
Modeling of the Response to Hypofractionated Stereotactic Pulmonary Irradiation
Identify 18-Fluorodeoxyglucose (18F-FDG) positron emission tomography-computed tomography (PET-CT) parameters predictive of tumor response and local control
- Trial name
- MUMOFRAT (NCT03175861)
- Testing
- Stereotactic radiotherapy
- Where
- 4 sites in France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Brest
Non-Small-Cell Lung Cancer, Pleural Effusion, Malignant
Non-small Cell Lung Cancer Registry
This trial will evaluate two separate groups of patients with stage IIIB/IV non-small cell lung cancer. The objective of Group 1 is to investigate an FDA-approved drug in stage IIIB/IV non-small cell lung cancer patients that has…
- Trial name
- NCT00099541
- Testing
- zoledronic acid
- Where
- 101 sites in United States
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Relapsed/Refractory Small Cell Lung Cancer
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
The main aim of this study is to: evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] by investigator) of 2 dose levels of tarlatamab for Part 1 only evaluate anti-tumor…
- Trial name
- DeLLphi-301 (NCT05060016)
- Testing
- Tarlatamab
- Where
- 80 sites in United States, Austria and 16 more
- Volunteers
- 222 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.